25 XP   0   0   10

Eiger Biopharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Eiger Biopharmaceuticals Inc together

PenkeI guess you are interested in Eiger Biopharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eiger Biopharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Eiger Biopharmaceuticals Inc

I send you an email if I find something interesting about Eiger Biopharmaceuticals Inc.

Quick analysis of Eiger Biopharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Eiger Biopharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-1.08
Expected worth in 1 year
$-3.95
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-2.86
Return On Investment
-139.7%

For what price can you sell your share?

Current Price per Share
$2.05
Expected price per share
$1.1 - $8.1
How sure are you?
50%

1. Valuation of Eiger Biopharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$2.05

Intrinsic Value Per Share

$-591.23 - $-232.33

Total Value Per Share

$-592.31 - $-233.42

2. Growth of Eiger Biopharmaceuticals Inc (5 min.)




Is Eiger Biopharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.6m$87.7m-$61.6m-236.6%

How much money is Eiger Biopharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$21.6m-$23.5m$1.8m8.7%
Net Profit Margin-623.3%-680.5%--

How much money comes from the company's main activities?

3. Financial Health of Eiger Biopharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#460 / 1007

Most Revenue
#269 / 1007

Most Profit
#962 / 1007

Most Efficient
#774 / 1007

What can you expect buying and holding a share of Eiger Biopharmaceuticals Inc? (5 min.)

Welcome investor! Eiger Biopharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Eiger Biopharmaceuticals Inc.

What can you expect buying and holding a share of Eiger Biopharmaceuticals Inc?

First you should know what it really means to hold a share of Eiger Biopharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Eiger Biopharmaceuticals Inc is $2.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eiger Biopharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eiger Biopharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.08. Based on the TTM, the Book Value Change Per Share is $-0.72 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eiger Biopharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-12.19-594.5%-14.64-714.2%-0.60-29.3%-3.39-165.2%-3.54-172.9%
Usd Book Value Change Per Share-11.42-557.2%-0.72-34.9%-0.21-10.4%-0.17-8.4%-0.39-18.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.021.0%0.021.2%
Usd Total Gains Per Share-11.42-557.2%-0.72-34.9%-0.21-10.4%-0.15-7.4%-0.36-17.7%
Usd Price Per Share0.31-0.77-6.83-7.56-9.30-
Price to Earnings Ratio-0.01--0.01--2.85--2.48--1.97-
Price-to-Total Gains Ratio-0.03--0.03--6.62-5.58-2.46-
Price to Book Ratio-0.28--0.04-3.08-2.75-2.50-
Price-to-Total Gains Ratio-0.03--0.03--6.62-5.58-2.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.05
Number of shares487
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.72-0.17
Usd Total Gains Per Share-0.72-0.15
Gains per Quarter (487 shares)-348.63-74.01
Gains per Year (487 shares)-1,394.50-296.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1395-140540-336-306
20-2789-280081-673-602
30-4184-4195121-1009-898
40-5578-5590161-1345-1194
50-6973-6985201-1682-1490
60-8367-8380242-2018-1786
70-9762-9775282-2354-2082
80-11156-11170322-2690-2378
90-12551-12565362-3027-2674
100-13945-13960403-3363-2970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.043.00.02.3%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%14.026.00.035.0%16.027.01.036.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%3.00.037.07.5%3.00.041.06.8%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%14.026.00.035.0%16.027.01.036.4%

Fundamentals of Eiger Biopharmaceuticals Inc

About Eiger Biopharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Fundamental data was last updated by Penke on 2024-04-11 06:45:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Eiger Biopharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Eiger Biopharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -561.9% means that $-5.62 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is -561.9%. The company is making a huge loss. -2
  • The TTM is -623.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-561.9%TTM-623.3%+61.5%
TTM-623.3%YOY-680.5%+57.2%
TTM-623.3%5Y-302.9%-320.4%
5Y-302.9%10Y-151.5%-151.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-561.9%-207.2%-354.7%
TTM-623.3%-216.8%-406.5%
YOY-680.5%-282.4%-398.1%
5Y-302.9%-434.0%+131.1%
10Y-151.5%-584.8%+433.3%
1.1.2. Return on Assets

Shows how efficient Eiger Biopharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • -32.4% Return on Assets means that Eiger Biopharmaceuticals Inc generated $-0.32 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is -32.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -26.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.4%TTM-26.2%-6.2%
TTM-26.2%YOY-16.2%-10.0%
TTM-26.2%5Y-15.8%-10.4%
5Y-15.8%10Y-18.1%+2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.4%-13.2%-19.2%
TTM-26.2%-12.7%-13.5%
YOY-16.2%-11.5%-4.7%
5Y-15.8%-13.8%-2.0%
10Y-18.1%-15.5%-2.6%
1.1.3. Return on Equity

Shows how efficient Eiger Biopharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Eiger Biopharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-61.4%+61.4%
TTM-61.4%YOY-27.5%-33.8%
TTM-61.4%5Y-30.4%-31.0%
5Y-30.4%10Y-31.8%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.7%+16.7%
TTM-61.4%-15.9%-45.5%
YOY-27.5%-14.7%-12.8%
5Y-30.4%-19.2%-11.2%
10Y-31.8%-20.0%-11.8%

1.2. Operating Efficiency of Eiger Biopharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Eiger Biopharmaceuticals Inc is operating .

  • Measures how much profit Eiger Biopharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -533.7% means the company generated $-5.34  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is -533.7%. The company is operating very inefficient. -2
  • The TTM is -599.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-533.7%TTM-599.7%+66.0%
TTM-599.7%YOY-647.2%+47.5%
TTM-599.7%5Y-286.7%-313.0%
5Y-286.7%10Y-143.3%-143.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-533.7%-298.0%-235.7%
TTM-599.7%-238.5%-361.2%
YOY-647.2%-291.9%-355.3%
5Y-286.7%-485.6%+198.9%
10Y-143.3%-610.8%+467.5%
1.2.2. Operating Ratio

Measures how efficient Eiger Biopharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 6.28 means that the operating costs are $6.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is 6.275. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.049. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.275TTM7.049-0.774
TTM7.049YOY7.462-0.413
TTM7.0495Y4.066+2.982
5Y4.06610Y2.033+2.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2753.235+3.040
TTM7.0493.310+3.739
YOY7.4623.791+3.671
5Y4.0665.675-1.609
10Y2.0337.558-5.525

1.3. Liquidity of Eiger Biopharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Eiger Biopharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.31 means the company has $3.31 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is 3.306. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.060. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.306TTM4.060-0.754
TTM4.060YOY5.037-0.977
TTM4.0605Y6.274-2.214
5Y6.27410Y8.398-2.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3063.877-0.571
TTM4.0604.178-0.118
YOY5.0375.343-0.306
5Y6.2746.135+0.139
10Y8.3986.468+1.930
1.3.2. Quick Ratio

Measures if Eiger Biopharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.19 means the company can pay off $3.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is 3.187. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.293. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.187TTM5.293-2.106
TTM5.293YOY7.758-2.465
TTM5.2935Y8.947-3.653
5Y8.94710Y11.566-2.620
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1873.514-0.327
TTM5.2933.998+1.295
YOY7.7585.380+2.378
5Y8.9476.135+2.812
10Y11.5666.434+5.132

1.4. Solvency of Eiger Biopharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Eiger Biopharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Eiger Biopharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.03 means that Eiger Biopharmaceuticals Inc assets are financed with 102.9% credit (debt) and the remaining percentage (100% - 102.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is 1.029. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.750. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.029TTM0.750+0.278
TTM0.750YOY0.405+0.346
TTM0.7505Y0.460+0.291
5Y0.46010Y0.372+0.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0290.339+0.690
TTM0.7500.336+0.414
YOY0.4050.271+0.134
5Y0.4600.368+0.092
10Y0.3720.388-0.016
1.4.2. Debt to Equity Ratio

Measures if Eiger Biopharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eiger Biopharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.680-1.680
TTM1.680YOY0.687+0.993
TTM1.6805Y0.856+0.824
5Y0.85610Y0.690+0.165
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM1.6800.403+1.277
YOY0.6870.340+0.347
5Y0.8560.430+0.426
10Y0.6900.463+0.227

2. Market Valuation of Eiger Biopharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eiger Biopharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Eiger Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.01 means the investor is paying $-0.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eiger Biopharmaceuticals Inc:

  • The EOD is -0.042. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.006. Based on the earnings, the company is expensive. -2
  • The TTM is -0.013. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.042MRQ-0.006-0.036
MRQ-0.006TTM-0.013+0.006
TTM-0.013YOY-2.853+2.841
TTM-0.0135Y-2.482+2.469
5Y-2.48210Y-1.968-0.514
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.042-2.281+2.239
MRQ-0.006-2.599+2.593
TTM-0.013-2.674+2.661
YOY-2.853-4.133+1.280
5Y-2.482-6.258+3.776
10Y-1.968-6.270+4.302
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eiger Biopharmaceuticals Inc:

  • The EOD is -0.052. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.008. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.013. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.052MRQ-0.008-0.044
MRQ-0.008TTM-0.013+0.005
TTM-0.013YOY-3.425+3.412
TTM-0.0135Y-2.964+2.950
5Y-2.96410Y-2.334-0.630
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.052-2.903+2.851
MRQ-0.008-3.323+3.315
TTM-0.013-3.552+3.539
YOY-3.425-5.592+2.167
5Y-2.964-8.378+5.414
10Y-2.334-8.875+6.541
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Eiger Biopharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.28 means the investor is paying $-0.28 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eiger Biopharmaceuticals Inc:

  • The EOD is -1.891. Based on the equity, the company is expensive. -2
  • The MRQ is -0.281. Based on the equity, the company is expensive. -2
  • The TTM is -0.036. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.891MRQ-0.281-1.610
MRQ-0.281TTM-0.036-0.245
TTM-0.036YOY3.078-3.114
TTM-0.0365Y2.753-2.789
5Y2.75310Y2.499+0.254
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.8911.911-3.802
MRQ-0.2812.116-2.397
TTM-0.0362.097-2.133
YOY3.0782.885+0.193
5Y2.7533.556-0.803
10Y2.4993.959-1.460
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eiger Biopharmaceuticals Inc.

3.1. Institutions holding Eiger Biopharmaceuticals Inc

Institutions are holding 43.862% of the shares of Eiger Biopharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Ameriprise Financial Inc16.910.00057505539-1086932-12.6498
2023-12-31Propel Bio Management LLC9.89390.8174439143243914320
2023-12-31683 Capital Management LLC4.73130.03862100000-550000-20.7547
2023-12-31Vanguard Group Inc4.102201820767-143535-7.3072
2023-12-31BlackRock Inc1.31510583730-302404-34.1262
2023-12-31Geode Capital Management, LLC0.8555037970700
2023-12-31Renaissance Technologies Corp0.77550.00013442103442100
2023-12-31RBF LLC0.76320.0046338733-52532-13.4262
2023-12-31Acadian Asset Management LLC0.39220.0002174088-63946-26.8642
2023-12-31State Street Corporation0.3307014678100
2023-12-31Northern Trust Corp0.2531011232300
2023-12-31Millennium Management LLC0.1828081144-188149-69.8678
2023-12-31Sequoia Financial Advisors LLC0.14190.00026300000
2023-12-31TWO SIGMA SECURITIES, LLC0.12890.0001572212143159.8799
2023-12-31Verition Fund Managegment, LLC0.12210.000154182-8300-13.2838
2023-12-31Bank of America Corp0.1084048121-2201-4.3738
2023-12-31Tocqueville Asset Management L.P.0.08410.000237325-13750-26.9212
2023-12-31Charles Schwab Investment Management Inc0.075303343600
2023-12-31TOWNSQUARE CAPITAL LLC0.07310.00013243000
2023-12-31DFPG Investments, Inc.0.07310.00063243000
Total 41.31240.862718336599+2345324+12.8%

3.2. Funds holding Eiger Biopharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Columbia Seligman Tech & Inf SMA Cmp5.22510.0045231915023190954216536.3636
2023-12-31Columbia Seligman Technology Growth5.22510.0045231915000
2024-02-29Simplify Propel Opportunities ETF6.08320.4329000000
2023-09-30BlackRock Extended Mkt Composite0.19280.00028559200
2024-02-29Columbia Seligman Tech & Info A5.22510.00367730500
2024-02-29Vanguard Total Stock Mkt Idx Inv2.803704148100
2023-12-31NT Ext Equity Mkt Idx Fd - L0.08460.00013753900
2023-12-31Northern Trust Extended Eq Market Idx0.08460.00013753900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.08120.00013601900
2024-02-29Columbia Seligman Global Tech A2.38810.0093533200
2023-09-30Perinvest(Lux) Sicav Glb Hlthcare Eq B0.07550.21823350000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06520.000128928540.187
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0569025269-1236555-97.9974
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.21830.00011802400
2023-12-31SSgA U.S. Extended Market Index Class I0.03420.00011518600
2024-02-29CT (Lux) Global Tech DU0.85460.007112643126430
2023-12-31NT Quality SCC US Fund - L0.02670.00111185700
2023-12-31NT Quality Small Cap Core0.02670.00111185700
2024-02-29Fidelity Extended Market Index0.45660.00016756-33-0.4861
2023-12-31SSgA U.S. Total Market Index Strategy0.009904380-101-2.254
Total 30.21810.6825247507+1095103+20.9%

3.3. Insider Transactions

Insiders are holding 11.799% of the shares of Eiger Biopharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-02Richard A KayneBUY7799
2023-10-31Richard A KayneBUY51617.2

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Eiger Biopharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---11.422-0.716-94%-0.214-98%-0.173-98%-0.387-97%
Book Value Per Share---1.08417.614-106%2.264-148%5.738-119%11.800-109%
Current Ratio--3.3064.060-19%5.037-34%6.274-47%8.398-61%
Debt To Asset Ratio--1.0290.750+37%0.405+154%0.460+124%0.372+177%
Debt To Equity Ratio---1.680-100%0.687-100%0.856-100%0.690-100%
Dividend Per Share----0%-0%0.021-100%0.025-100%
Eps---12.187-14.641+20%-0.602-95%-3.387-72%-3.545-71%
Free Cash Flow Per Share---9.837-14.075+43%-0.499-95%-3.361-66%-3.264-67%
Free Cash Flow To Equity Per Share---9.827-14.080+43%0.030-33130%-2.825-71%-0.721-93%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---232.333--------
Intrinsic Value_10Y_min---591.228--------
Intrinsic Value_1Y_max---14.557--------
Intrinsic Value_1Y_min---27.352--------
Intrinsic Value_3Y_max---50.387--------
Intrinsic Value_3Y_min---110.291--------
Intrinsic Value_5Y_max---94.233--------
Intrinsic Value_5Y_min---223.403--------
Market Cap3032954.500+85%451244.4501141389.548-60%267947845.710-100%211536150.139-100%138264516.379-100%
Net Profit Margin---5.619-6.233+11%-6.805+21%-3.029-46%-1.515-73%
Operating Margin---5.337-5.997+12%-6.472+21%-2.867-46%-1.433-73%
Operating Ratio--6.2757.049-11%7.462-16%4.066+54%2.033+209%
Pb Ratio-1.891-572%-0.281-0.036-87%3.078-109%2.753-110%2.499-111%
Pe Ratio-0.042-572%-0.006-0.013+103%-2.853+45501%-2.482+39565%-1.968+31357%
Price Per Share2.050+85%0.3050.771-60%6.830-96%7.559-96%9.295-97%
Price To Free Cash Flow Ratio-0.052-572%-0.008-0.013+70%-3.425+44089%-2.964+38135%-2.334+30011%
Price To Total Gains Ratio-0.179-572%-0.027-0.028+5%-6.620+24693%5.579-100%2.462-101%
Quick Ratio--3.1875.293-40%7.758-59%8.947-64%11.566-72%
Return On Assets---0.324-0.262-19%-0.162-50%-0.158-51%-0.181-44%
Return On Equity----0.6140%-0.2750%-0.3040%-0.3180%
Total Gains Per Share---11.422-0.716-94%-0.214-98%-0.152-99%-0.362-97%
Usd Book Value---1604000.00026060000.000-106%87724750.000-102%70161700.000-102%55333850.000-103%
Usd Book Value Change Per Share---11.422-0.716-94%-0.214-98%-0.173-98%-0.387-97%
Usd Book Value Per Share---1.08417.614-106%2.264-148%5.738-119%11.800-109%
Usd Dividend Per Share----0%-0%0.021-100%0.025-100%
Usd Eps---12.187-14.641+20%-0.602-95%-3.387-72%-3.545-71%
Usd Free Cash Flow---14554000.000-20824500.000+43%-19444250.000+34%-20214350.000+39%-14681450.000+1%
Usd Free Cash Flow Per Share---9.837-14.075+43%-0.499-95%-3.361-66%-3.264-67%
Usd Free Cash Flow To Equity Per Share---9.827-14.080+43%0.030-33130%-2.825-71%-0.721-93%
Usd Market Cap3032954.500+85%451244.4501141389.548-60%267947845.710-100%211536150.139-100%138264516.379-100%
Usd Price Per Share2.050+85%0.3050.771-60%6.830-96%7.559-96%9.295-97%
Usd Profit---18030000.000-21661750.000+20%-23537000.000+31%-17237400.000-4%-13865450.000-23%
Usd Revenue--3209000.0003666500.000-12%3537000.000-9%1879800.000+71%939900.000+241%
Usd Total Gains Per Share---11.422-0.716-94%-0.214-98%-0.152-99%-0.362-97%
 EOD+6 -2MRQTTM+15 -17YOY+9 -235Y+5 -2910Y+5 -29

4.2. Fundamental Score

Let's check the fundamental score of Eiger Biopharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.042
Price to Book Ratio (EOD)Between0-1-1.891
Net Profit Margin (MRQ)Greater than0-5.619
Operating Margin (MRQ)Greater than0-5.337
Quick Ratio (MRQ)Greater than13.187
Current Ratio (MRQ)Greater than13.306
Debt to Asset Ratio (MRQ)Less than11.029
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.324
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Eiger Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.904
Ma 20Greater thanMa 503.755
Ma 50Greater thanMa 1005.207
Ma 100Greater thanMa 2006.572
OpenGreater thanClose1.610
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Total Stockholder Equity 78,308-22,99855,310-20,07135,239-19,94415,295-16,899-1,604
Interest Expense  1,0921281,220651,285581,343-2,755-1,412



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets55,654
Total Liabilities57,258
Total Stockholder Equity-1,604
 As reported
Total Liabilities 57,258
Total Stockholder Equity+ -1,604
Total Assets = 55,654

Assets

Total Assets55,654
Total Current Assets54,624
Long-term Assets1,030
Total Current Assets
Cash And Cash Equivalents 27,501
Short-term Investments 11,920
Net Receivables 1,321
Inventory 1,105
Other Current Assets 12,777
Total Current Assets  (as reported)54,624
Total Current Assets  (calculated)54,624
+/-0
Long-term Assets
Property Plant Equipment 886
Long-term Assets Other 144
Long-term Assets  (as reported)1,030
Long-term Assets  (calculated)1,030
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities16,524
Long-term Liabilities40,734
Total Stockholder Equity-1,604
Total Current Liabilities
Short-term Debt 205
Accounts payable 4,858
Other Current Liabilities -459
Total Current Liabilities  (as reported)16,524
Total Current Liabilities  (calculated)4,604
+/- 11,920
Long-term Liabilities
Long-term Liabilities Other 40,734
Long-term Liabilities  (as reported)40,734
Long-term Liabilities  (calculated)40,734
+/-0
Total Stockholder Equity
Common Stock44
Retained Earnings -498,702
Accumulated Other Comprehensive Income -86
Other Stockholders Equity 497,140
Total Stockholder Equity (as reported)-1,604
Total Stockholder Equity (calculated)-1,604
+/-0
Other
Capital Stock44
Cash and Short Term Investments 39,421
Common Stock Shares Outstanding 1,477
Current Deferred Revenue11,920
Liabilities and Stockholders Equity 55,654
Net Debt 13,438
Net Invested Capital 39,130
Net Working Capital 38,100
Property Plant and Equipment Gross 886
Short Long Term Debt Total 40,939



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-30
> Total Assets 
0
35,929
0
28,386
24,588
21,154
58,578
52,278
96,909
89,110
73,239
59,953
38,236
33,886
61,873
46,771
57,427
60,736
49,767
41,460
33,281
42,882
34,221
75,338
67,378
102,448
93,108
132,927
119,995
105,139
88,423
103,157
140,693
143,594
175,515
156,838
140,277
126,402
153,329
163,691
143,744
120,139
99,228
72,358
55,654
55,65472,35899,228120,139143,744163,691153,329126,402140,277156,838175,515143,594140,693103,15788,423105,139119,995132,92793,108102,44867,37875,33834,22142,88233,28141,46049,76760,73657,42746,77161,87333,88638,23659,95373,23989,11096,90952,27858,57821,15424,58828,386035,9290
   > Total Current Assets 
0
32,937
0
28,281
23,396
18,550
58,214
51,762
96,013
88,083
72,261
59,210
38,093
33,876
61,672
46,559
57,206
60,517
49,553
41,278
33,125
42,491
33,864
74,977
66,804
101,845
88,386
128,368
114,410
100,384
82,465
97,339
134,942
137,806
169,886
118,803
99,086
103,364
147,356
157,703
142,289
117,535
96,911
70,484
54,624
54,62470,48496,911117,535142,289157,703147,356103,36499,086118,803169,886137,806134,94297,33982,465100,384114,410128,36888,386101,84566,80474,97733,86442,49133,12541,27849,55360,51757,20646,55961,67233,87638,09359,21072,26188,08396,01351,76258,21418,55023,39628,281032,9370
       Cash And Cash Equivalents 
0
13,841
0
8,319
9,955
7,903
53,877
13,371
14,367
14,435
50,018
50,041
37,092
32,777
61,197
45,399
56,294
27,756
14,451
11,197
13,078
32,035
33,247
33,323
16,927
61,262
63,407
58,421
19,406
39,373
22,629
62,813
51,993
28,864
108,410
65,056
49,255
22,221
46,562
36,572
26,308
25,798
15,181
22,983
27,501
27,50122,98315,18125,79826,30836,57246,56222,22149,25565,056108,41028,86451,99362,81322,62939,37319,40658,42163,40761,26216,92733,32333,24732,03513,07811,19714,45127,75656,29445,39961,19732,77737,09250,04150,01814,43514,36713,37153,8777,9039,9558,319013,8410
       Short-term Investments 
0
18,808
0
19,658
13,258
10,467
3,752
37,801
80,755
70,513
20,570
8,004
0
0
0
0
0
32,180
34,573
29,112
19,264
9,744
9,744
40,169
48,013
39,091
22,385
66,914
90,545
55,621
54,978
27,962
73,341
99,976
52,082
42,311
36,051
66,594
86,155
105,220
94,736
73,150
60,091
30,626
11,920
11,92030,62660,09173,15094,736105,22086,15566,59436,05142,31152,08299,97673,34127,96254,97855,62190,54566,91422,38539,09148,01340,1699,7449,74419,26429,11234,57332,180000008,00420,57070,51380,75537,8013,75210,46713,25819,658018,8080
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
158
185
67
226
226
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
803
0
639
1,438
2,762
2,576
2,287
1,038
2,458
1,749
3,891
3,715
1,321
1,3213,7153,8911,7492,4581,0382,2872,5762,7621,438639080300000000000000000226226671851580000000000
       Other Current Assets 
0
288
0
304
183
180
585
590
891
3,135
1,515
980
934
873
475
1,160
912
581
529
969
783
712
617
1,485
1,864
1,492
2,594
3,033
4,459
5,390
4,858
6,564
8,805
1,215
1,941
1,310
1,354
9,361
2,000
1,762
1,794
13,985
975
1,134
12,777
12,7771,13497513,9851,7941,7622,0009,3611,3541,3101,9411,2158,8056,5644,8585,3904,4593,0332,5941,4921,8641,4856177127839695295819121,1604758739349801,5153,13589159058518018330402880
   > Long-term Assets 
0
2,992
0
105
1,192
2,604
364
516
896
1,027
978
743
143
10
201
212
221
219
214
182
156
391
357
361
574
603
4,722
4,559
5,585
4,755
5,958
5,818
5,751
5,788
5,629
38,035
41,191
23,038
5,973
5,988
1,455
2,604
2,317
1,874
1,030
1,0301,8742,3172,6041,4555,9885,97323,03841,19138,0355,6295,7885,7515,8185,9584,7555,5854,5594,722603574361357391156182214219221212201101437439781,0278965163642,6041,19210502,9920
       Property Plant Equipment 
0
122
0
97
85
308
353
367
616
763
793
616
133
41
46
67
79
76
90
101
90
79
68
71
185
167
2,016
1,961
2,197
2,244
2,177
2,037
1,970
1,885
1,708
1,524
1,358
1,266
1,066
910
757
1,257
1,250
1,084
886
8861,0841,2501,2577579101,0661,2661,3581,5241,7081,8851,9702,0372,1772,2442,1971,9612,01616718571687990101907679674641133616793763616367353308859701220
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,426
35,093
17,262
0
0
0
0
0
0
0
000000017,26235,09332,42600000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
11
149
280
264
185
127
10
46
155
145
142
143
124
81
66
312
289
290
389
436
2,706
2,598
3,388
2,511
3,781
3,781
3,781
5,079
4,970
4,085
4,740
4,510
4,907
5,078
698
1,347
0
0
0
0001,3476985,0784,9074,5104,7404,0854,9705,0793,7813,7813,7812,5113,3882,5982,7064363892902893126681124143142145155461012718526428014911000000
> Total Liabilities 
0
59,531
0
7,913
3,301
12,047
3,997
3,714
14,934
17,006
15,135
17,129
1,826
2,333
8,126
2,804
5,362
20,015
18,897
20,788
20,726
20,360
19,490
26,057
33,611
35,856
42,300
44,848
48,336
48,659
45,202
44,666
47,743
48,559
49,325
47,713
50,812
54,003
56,062
60,766
65,436
64,829
63,989
57,063
57,258
57,25857,06363,98964,82965,43660,76656,06254,00350,81247,71349,32548,55947,74344,66645,20248,65948,33644,84842,30035,85633,61126,05719,49020,36020,72620,78818,89720,0155,3622,8048,1262,3331,82617,12915,13517,00614,9343,7143,99712,0473,3017,913059,5310
   > Total Current Liabilities 
0
1,778
0
2,421
3,261
6,560
3,962
3,668
4,912
6,606
6,134
16,836
1,797
2,309
8,111
2,789
5,347
5,288
4,097
5,890
5,733
7,269
7,502
8,832
14,541
10,024
10,825
13,317
16,745
16,949
13,433
16,147
21,660
16,627
17,517
15,875
22,012
29,901
36,612
21,847
26,119
25,121
23,999
16,713
16,524
16,52416,71323,99925,12126,11921,84736,61229,90122,01215,87517,51716,62721,66016,14713,43316,94916,74513,31710,82510,02414,5418,8327,5027,2695,7335,8904,0975,2885,3472,7898,1112,3091,79716,8366,1346,6064,9123,6683,9626,5603,2612,42101,7780
       Short-term Debt 
0
0
0
0
0
1,044
0
0
0
1
1,671
10,587
0
5,444
0
0
0
14,727
14,800
14,898
14,993
2,002
3,253
3,242
6,565
0
439
452
466
534
551
3,831
6,348
582
599
590
3,680
8,437
13,139
436
277
491
435
321
205
20532143549127743613,1398,4373,6805905995826,3483,83155153446645243906,5653,2423,2532,00214,99314,89814,80014,7270005,444010,5871,67110001,04400000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
1
0
0
0
5,444
0
0
0
14,727
14,800
14,898
14,993
2,002
3,253
3,242
6,565
0
439
0
0
0
0
3,283
5,783
0
0
0
3,072
7,809
12,549
0
0
0
0
0
0
00000012,5497,8093,0720005,7833,283000043906,5653,2423,2532,00214,99314,89814,80014,7270005,4440001000000000
       Accounts payable 
0
569
0
699
1,005
1,397
731
1,088
2,198
5,803
2,790
2,761
228
479
6,062
1,254
4,075
2,639
3,187
4,468
4,167
3,183
3,025
4,438
6,517
5,830
5,523
7,194
9,057
6,414
8,873
5,180
8,250
4,640
7,747
4,444
6,753
7,765
9,218
9,945
10,497
8,975
11,858
4,946
4,858
4,8584,94611,8588,97510,4979,9459,2187,7656,7534,4447,7474,6408,2505,1808,8736,4149,0577,1945,5235,8306,5174,4383,0253,1834,1674,4683,1872,6394,0751,2546,0624792282,7612,7905,8032,1981,0887311,3971,00569905690
       Other Current Liabilities 
0
1,209
0
1,722
2,256
1,116
3,231
2,580
2,714
1
1,673
3,488
1,569
1,830
2,049
1,535
1,272
2,649
910
1,422
1,566
2,028
1,174
1,132
1,429
4,194
439
5,651
7,152
9,961
4,009
7,136
7,062
11,405
9,171
10,841
11,579
13,699
14,255
9,677
13,310
14,282
10,018
-19,180
-459
-459-19,18010,01814,28213,3109,67714,25513,69911,57910,8419,17111,4057,0627,1364,0099,9617,1525,6514394,1941,4291,1321,1742,0281,5661,4229102,6491,2721,5352,0491,8301,5693,4881,67312,7142,5803,2311,1162,2561,72201,2090
   > Long-term Liabilities 
0
57,753
0
5,492
40
5,487
35
46
10,022
10,400
9,001
293
29
24
15
15
15
14,727
14,800
14,898
14,993
13,091
11,988
17,225
19,070
25,832
31,475
31,531
31,591
31,710
31,769
28,519
26,083
31,932
31,808
31,838
28,800
24,102
19,450
38,919
39,317
39,708
39,990
40,350
40,734
40,73440,35039,99039,70839,31738,91919,45024,10228,80031,83831,80831,93226,08328,51931,76931,71031,59131,53131,47525,83219,07017,22511,98813,09114,99314,89814,80014,72715151524292939,00110,40010,02246355,487405,492057,7530
       Long term Debt Total 
0
0
0
0
0
0
0
0
9,911
10,102
8,710
10
0
0
0
0
0
14,727
14,800
14,898
14,993
13,091
11,938
17,032
18,856
25,620
29,844
30,019
30,202
30,390
30,581
27,495
25,200
31,194
31,218
31,403
28,524
23,986
19,446
38,916
39,315
39,625
39,989
40,349
0
040,34939,98939,62539,31538,91619,44623,98628,52431,40331,21831,19425,20027,49530,58130,39030,20230,01929,84425,62018,85617,03211,93813,09114,99314,89814,80014,72700000108,71010,1029,91100000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
298
0
0
0
2,344
15
15
15
0
0
0
0
0
50
193
214
212
0
0
0
0
0
0
0
0
0
0
28,800
0
0
0
0
0
0
0
0
0000000028,800000000000021221419350000001515152,344000298000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
35
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000035000000
> Total Stockholder Equity
0
-23,602
0
20,473
21,287
9,107
54,581
48,564
81,975
72,104
58,104
42,824
36,410
31,553
53,747
43,967
52,065
40,721
30,870
20,672
12,555
22,522
14,731
49,281
33,767
66,592
50,808
88,079
71,659
56,480
43,221
58,491
92,950
95,035
126,190
109,125
89,465
72,399
97,267
102,925
78,308
55,310
35,239
15,295
-1,604
-1,60415,29535,23955,31078,308102,92597,26772,39989,465109,125126,19095,03592,95058,49143,22156,48071,65988,07950,80866,59233,76749,28114,73122,52212,55520,67230,87040,72152,06543,96753,74731,55336,41042,82458,10472,10481,97548,56454,5819,10721,28720,4730-23,6020
   Common Stock
0
0
0
1
1
0
18
18
23
23
24
24
24
2
7
7
8
8
8
8
8
11
11
14
14
19
19
24
24
24
24
27
32
34
34
34
34
35
41
44
44
44
44
44
44
4444444444444135343434343227242424241919141411118888877224242423231818011000
   Retained Earnings Total Equity0-480,672-459,977-437,193-412,055-384,944-363,060-340,417-318,649-296,426-277,252-306,500-287,694-272,014-256,688-241,449-224,529-205,913-188,386-171,197-154,696-137,552-127,637-118,806-107,913-98,743-87,597-76,358-63,590-52,220-39,019-190,852-186,106-179,710-163,185-146,439-135,098-126,740-119,748000000
   Accumulated Other Comprehensive Income 
0
9
0
2
7
2
-58,578
18
-8
-8
-1
-150
-287
-13
-13
0
0
-15
-8
-6
-2
-3
-107
-14
-6
-25
5
5
43
42
36
45
16
-8
-5
-6
1
-149
-522
-761
-620
-300
-170
-164
-86
-86-164-170-300-620-761-522-1491-6-5-8164536424355-25-6-14-107-3-2-6-8-1500-13-13-287-150-1-8-818-58,578272090
   Capital Surplus 
0
0
0
0
0
0
174,311
175,268
217,058
218,528
221,266
222,510
222,492
222,403
92,759
96,180
115,647
117,086
118,467
119,413
120,462
141,320
142,357
186,833
188,455
237,795
239,170
293,963
296,121
297,863
299,849
330,433
380,596
401,509
403,413
405,523
408,079
412,930
460,808
488,586
490,939
492,759
495,342
496,087
0
0496,087495,342492,759490,939488,586460,808412,930408,079405,523403,413401,509380,596330,433299,849297,863296,121293,963239,170237,795188,455186,833142,357141,320120,462119,413118,467117,086115,64796,18092,759222,403222,492222,510221,266218,528217,058175,268174,311000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
68,980
0
61,326
127,686
61,593
174,311
122,990
120,149
218,528
221,266
222,510
222,492
222,403
92,759
96,180
115,647
117,086
118,467
119,413
120,462
141,320
142,357
186,833
188,455
237,795
239,170
293,963
296,121
297,863
299,849
330,433
380,596
401,509
403,413
405,523
408,079
412,930
460,808
488,586
490,939
492,759
495,342
496,087
497,140
497,140496,087495,342492,759490,939488,586460,808412,930408,079405,523403,413401,509380,596330,433299,849297,863296,121293,963239,170237,795188,455186,833142,357141,320120,462119,413118,467117,086115,64796,18092,759222,403222,492222,510221,266218,528120,149122,990174,31161,593127,68661,326068,9800



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue14,666
Cost of Revenue-268
Gross Profit14,39814,398
 
Operating Income (+$)
Gross Profit14,398
Operating Expense-98,309
Operating Income-83,643-83,911
 
Operating Expense (+$)
Research Development69,238
Selling General Administrative28,803
Selling And Marketing Expenses-
Operating Expense98,30998,041
 
Net Interest Income (+$)
Interest Income2,325
Interest Expense-5,260
Other Finance Cost-0
Net Interest Income-2,935
 
Pretax Income (+$)
Operating Income-83,643
Net Interest Income-2,935
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-86,646-83,575
EBIT - interestExpense = -5,260
-86,647
-81,387
Interest Expense5,260
Earnings Before Interest and Taxes (EBIT)--81,386
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-86,646
Tax Provision-1
Net Income From Continuing Ops-86,647-86,647
Net Income-86,647
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-682,935
 

Technical Analysis of Eiger Biopharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eiger Biopharmaceuticals Inc. The general trend of Eiger Biopharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eiger Biopharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eiger Biopharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.2 < 7.9194 < 8.1.

The bearish price targets are: 1.1.

Tweet this
Eiger Biopharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eiger Biopharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eiger Biopharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eiger Biopharmaceuticals Inc. The current macd is -1.11110603.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eiger Biopharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eiger Biopharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eiger Biopharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Eiger Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEiger Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eiger Biopharmaceuticals Inc. The current adx is 21.68.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Eiger Biopharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Eiger Biopharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eiger Biopharmaceuticals Inc. The current sar is 2.77490835.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Eiger Biopharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eiger Biopharmaceuticals Inc. The current rsi is 32.90. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Eiger Biopharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEiger Biopharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eiger Biopharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eiger Biopharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Eiger Biopharmaceuticals Inc Daily Stochastic Oscillator ChartEiger Biopharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eiger Biopharmaceuticals Inc. The current cci is -77.8437062.

Eiger Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEiger Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eiger Biopharmaceuticals Inc. The current cmo is -34.28897846.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Eiger Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEiger Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eiger Biopharmaceuticals Inc. The current willr is -81.18811881.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Eiger Biopharmaceuticals Inc Daily Williams %R ChartEiger Biopharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eiger Biopharmaceuticals Inc.

Eiger Biopharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eiger Biopharmaceuticals Inc. The current atr is 0.81163615.

Eiger Biopharmaceuticals Inc Daily Average True Range (ATR) ChartEiger Biopharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eiger Biopharmaceuticals Inc. The current obv is 2,535,327.

Eiger Biopharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEiger Biopharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eiger Biopharmaceuticals Inc. The current mfi is 63.64.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Eiger Biopharmaceuticals Inc Daily Money Flow Index (MFI) ChartEiger Biopharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eiger Biopharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Eiger Biopharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eiger Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.904
Ma 20Greater thanMa 503.755
Ma 50Greater thanMa 1005.207
Ma 100Greater thanMa 2006.572
OpenGreater thanClose1.610
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Eiger Biopharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Eiger Biopharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eiger Biopharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eiger Biopharmaceuticals Inc

I send you an email if I find something interesting about Eiger Biopharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eiger Biopharmaceuticals Inc.

Receive notifications about Eiger Biopharmaceuticals Inc in your mailbox!